Consensus or Controversy? Investigator Perspectives on the Current and Future Role of Immune Checkpoint Inhibitors in the Management of Hepatobiliary Cancers

Om avsnittet

Dr Ahmed Omar Kaseb from the University of Texas MD Anderson Cancer Center in Houston, Texas, and Prof Arndt Vogel from Schwartz Reisman Liver Research Centre in Toronto, Ontario, discuss the optimal selection and sequencing of checkpoint inhibitor therapy for patients with hepatobiliary cancers, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

Om avsnittet

Fler avsnitt

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies

Lung Cancer — Proceedings from a Symposium Held in Conjunction with the American Oncology Network

Prostate Cancer with PTEN Deficiency — An Interview with Dr Neeraj Agarwal

HER2-Positive Gynecologic Cancers — Microlearning Activity 2: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Held in Conjunction with the American Oncology Network

Ovarian and Endometrial Cancer — Proceedings from a Symposium Held in Conjunction with the American Oncology Network

For Oncology Nurses: Non-Small Cell Lung Cancer with a ROS1 Fusion — An Interview with Dr Alexander E Drilon

Glucocorticoid Receptor Antagonists for Ovarian Cancer — An Interview with Professor Nicoletta Colombo

Gastroesophageal Cancers — Proceedings from a Symposium Held in Conjunction with the American Oncology Network

Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Conjunction with the American Oncology Network